Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 5Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1Liposarcoma 1Leiomyosarcoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Bone Neoplasms 1

Interventions

Doxorubicin 25Radiotherapy 16Ifosfamide 14Trabectedin 10pazopanib 6ribociclib 5pembrolizumab 5Specimen Handling 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Biopsy 5palbociclib 4Radiation 4Docetaxel 4Chemotherapy, Adjuvant 4selinexor 3liposomal doxorubicin 3eribulin 3abemaciclib 3X-Rays 3Vincristine 3Neoadjuvant Therapy 3Imatinib Mesylate 3Filgrastim 3Etoposide 3Cyclophosphamide 3toripalimab 2temsirolimus 2romidepsin 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma × ridaforolimus × Sarcoma × Clear all
NCT00093080 2015-02-13

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
216 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Neoplasm Metastasis, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡